A first-in-human multi-center phase 1/2 study of a selective FGFR2/3 inhibitor, CGT4859, in patients with intrahepatic cholangiocarcinomas or other advanced solid tumors.

Authors: Lipika Goyal, Haley Ellis, Mitesh Borad, Richard D. Kim, Jordi Rodon Ahnert, Alexander Starodub, Juan W. Valle, John Bridgewater, Jeffery Russell, Akza Ali, Kevin Moynihan, Meredith Little, Liangxing Zou, Julia Lawrence, Arndt Vogel

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps3171

Source: Full article

---

Abstract

TPS3171